ANI Pharmaceuticals' stock surged 8.08% in the pre-market trading session on Friday, following the company's impressive fourth-quarter 2024 earnings report that exceeded Wall Street's expectations.
The pharmaceutical company reported adjusted earnings per share of $1.63, significantly beating the analyst consensus estimate of $1.44. Moreover, ANI Pharmaceuticals' quarterly sales of $190.57 million surpassed the estimated $175.37 million, representing a 44.75% year-over-year increase.
The strong financial results, driven by robust sales growth and better-than-expected profitability, have fueled investor confidence in ANI Pharmaceuticals' prospects, leading to the pre-market stock rally.